New target for lung fibrosis

Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.

X-ray of lungs

Lung disorder drug regimen found harmful

Longtime treatment for IPF ineffective and even dangerous.